Tren Terapi Diabetes dengan GLP-1 Receptor Agonist
DOI:
https://doi.org/10.55175/cdk.v45i4.803Kata Kunci:
GLP-1, GLP-1-RA, inkretinAbstrak
GLP-1 menjadi target terapi DM tipe 2. Analog GLP-1 memiliki aktivitas serupa GLP-1 endogen, namun dengan kelebihan resisten terhadap deaktivasi enzim DPP-4, menghasilkan aktivitas yang lebih panjang. Manfaat lain obat golongan ini adalah menurunkan kadar hormon glukagon, memperlambat pengosongan lambung, dan menginduksi rasa kenyang.
GLP-1 becomes a therapeutic target of type 2 DM. Analogue of GLP-1 has the activity that mimics endogenous GLP-1, with advantages to be resistant to DPP-4 enzyme deactivation, resulting in longer activity. Other activities of this class are to lower glucagon hormone level, slow gastric emptying and induce satiety.
Unduhan
Referensi
Soelistijo SA. Novia H, Rudijanto A, Soewondo P, Suastika K, Manaf A, et al. Konsensus pengelolaan dan pencegahan diabetes mellitus tipe 2 di Indonesia 2015. 1st ed. Jakarta: PB Perkeni; 2015.
American Diabetes Association. Statistics about diabetes. Overall numbers, diabetes and prediabetes [Internet]. 2017 [cited 2017 Oct 13]. Available from: http://www.diabetes.org/diabetes-basics/statistics/?referrer=https://www.google.co.id/.
International Diabetes Federation. Diabetes atlas 2015 seventh edition [Internet]. 2015 [cited 2017 Oct 07]. Available from: http://www.dmthai.org/sites/default/files/idf_atlas_2015_uk_0.pdf.
American Diabetes Association. Standads of medical care in diabetes – 2017. Diabetes Care 2017;40(1):1-135.
DeFronzo RA. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–95. doi: 10.2337/db09-9028.
McDougall C, McKay GA, Fisher M. Drugs for diabetes. Part 6 GLP-1 receptor agonists. Br J Cardiol. 2011;18(4):167-9.
Byrne MM, Sturis J, Sobel RJ, Polonsky KS. Elevated plasma glucose 2 h postchallenge predicts defects in beta cell function. Am J Physiol. 1996;270(4 pt 1):572 9.
Bergstrom RW, Wahl PW, Leonetti DL, Fujimoto WY. Association of fasting glucose levels with a delayed secretion of insulin after oral glucose in subjects with glucose intolerance. J Clin Endocrinol Metab. 1990;71:1447 53.
Garber AJ. Long-acting glucagon-like peptide1 receptor agonists. Diabetes care 2011;34(2):279-84.
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131–57.
Tran KL, Park YI, Pandya S, Muliyil NJ, Jensen BD, Huynh K, et al. Overview of glucagon-like peptide-1 receptor agonists for the treatment of patients with type 2 diabetes. Am Health Drug Benefits. 2017;10(4):178-88.
Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368:1696–705.
Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non insulin dependent) diabetes. Diabetologia 1986;29:46 52.
Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 2002;45:1111 9.
Uccellatore A, Genovese S, Dicembrini I, Mannucci E, Cerello A. Comparison review of short-acting and long-acting glucagon-like peptide-1 receptor agonists. Diabetes Ther. 2015;6:239–56. DOI: 10.1007/s13300-015-0127-x.
Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: Efficacy and safety in diabetes and beyond. Drugs in Context 2015;4:212283. DOI: 10.7573/dic.212283.
Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: A review of head to-head clinical studies. Ther Adv Endocrinol Metab. 2015;6(1):19-28.
Highlights of prescribing information Byetta. [Internet]. 2009 [cited 2017 Oct 06]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf.
Highlights of prescribing information Victoza. [Internet]. 2010 [cited 2017 Oct 06]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022341lbl.pdf.
Kalra S, Baruah MP, Sahay RK, Unnikrishnan AG, Uppal S, Adetunji O. Glucagon like peptide 1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future. Indian J Endocrinol Metab. 2016;20(2):254–67. doi: 10.4103/2230 8210.176351.
Summary of product characteristics Bydureon. [Internet]. 2012 [cited 2017 Oct 06]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022200Orig1s008.pdf
Highlights of prescribing information Tanzeum. [Internet]. 2015 [cited 2017 Oct 06]. Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Tanzeum/pdf/TANZEUM-PI-MG-IFU-COMBINED.PDF.
Highlights of prescribing information Trulicity. [Internet]. 2017 [cited 2017 Oct 06]. Available from : http://pi.lilly.com/us/trulicity-uspi.pdf
Summary of product characteristics Lyxumia. [Internet]. 2016 [cited 2017 Oct 06]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002445/WC500140401.pdf.
Tibble AC, Cavaiola TS, Henry RR. Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: A review of current literature. Expert Rev Endocrinol Metab. 2013;8(3):247-59.
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2018 https://creativecommons.org/licenses/by-nc/4.0/
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
